Several other agents that have been identified as HIF-1α inhibitors including YC-1, PX-12, and PX-478 have exhibited efficacy in both in vitro and in vivo tumor models, further validating HIF as a therapeutic target [29], [30], [31]. The gene discussed is HIF1A; the disease is neoplasm.